<?xml version="1.0" encoding="UTF-8"?>
<researchReports>

    <report>
        <title>Nestlé SA - Organisches Wachstum übertrifft Erwartungen</title>
        <analyst>
            <name>Dr. Elena Fischer</name>
            <analystId>1</analystId>
        </analyst>
        <security>
            <ticker>NESN</ticker>
            <securityId>1</securityId>
            <name>Nestlé SA</name>
            <isin>CH0038863350</isin>
            <exchange>SIX</exchange>
            <currency>CHF</currency>
        </security>
        <publishedAt>2026-02-20T09:30:00</publishedAt>
        <reportType>UPDATE</reportType>
        <rating>BUY</rating>
        <previousRating>HOLD</previousRating>
        <targetPrice>105.00</targetPrice>
        <previousTarget>92.00</previousTarget>
        <currentPrice>96.50</currentPrice>
        <riskLevel>LOW</riskLevel>
        <executiveSummary>Test-Zusammenfassung für Nestlé</executiveSummary>
        <catalysts>
            <catalyst>Organisches Wachstum über 4%</catalyst>
            <catalyst>Portfolio-Bereinigung steigert Marge</catalyst>
        </catalysts>
        <risks>
            <risk>Input-Kosten bleiben volatil</risk>
            <risk>Währungseffekte CHF/USD</risk>
        </risks>
        <tags>
            <tag>Consumer Staples</tag>
            <tag>Large Cap</tag>
        </tags>
    </report>

    <report>
        <title>UBS Group - Integration auf Kurs</title>
        <analyst>
            <name>Thomas Brunner</name>
            <analystId>2</analystId>
        </analyst>
        <security>
            <ticker>UBSG</ticker>
            <securityId>4</securityId>
            <name>UBS Group AG</name>
            <isin>CH0244767585</isin>
            <exchange>SIX</exchange>
            <currency>CHF</currency>
        </security>
        <publishedAt>2026-02-19T08:15:00</publishedAt>
        <reportType>QUARTERLY</reportType>
        <rating>BUY</rating>
        <previousRating>BUY</previousRating>
        <targetPrice>32.50</targetPrice>
        <previousTarget>30.00</previousTarget>
        <currentPrice>28.40</currentPrice>
        <riskLevel>MEDIUM</riskLevel>
        <executiveSummary>Test-Zusammenfassung für UBS</executiveSummary>
        <catalysts>
            <catalyst>Kostensynergien über Plan</catalyst>
        </catalysts>
        <risks>
            <risk>Regulatorische Risiken</risk>
            <risk>Rechtsrisiken aus CS-Altlasten</risk>
        </risks>
        <tags>
            <tag>Financials</tag>
            <tag>Banking</tag>
        </tags>
    </report>

    <report>
        <title>Roche Holding - Diagnostik als Werttreiber</title>
        <analyst>
            <name>Dr. Elena Fischer</name>
            <analystId>1</analystId>
        </analyst>
        <security>
            <ticker>ROG</ticker>
            <securityId>3</securityId>
            <name>Roche Holding AG</name>
            <isin>CH0012032048</isin>
            <exchange>SIX</exchange>
            <currency>CHF</currency>
        </security>
        <publishedAt>2026-02-21T11:45:00</publishedAt>
        <reportType>UPDATE</reportType>
        <rating>HOLD</rating>
        <previousRating>HOLD</previousRating>
        <targetPrice>260.00</targetPrice>
        <previousTarget>255.00</previousTarget>
        <currentPrice>248.30</currentPrice>
        <riskLevel>MEDIUM</riskLevel>
        <executiveSummary>Test-Zusammenfassung für Roche</executiveSummary>
        <catalysts>
            <catalyst>Diagnostik-Wachstum 7% organisch</catalyst>
        </catalysts>
        <risks>
            <risk>Biosimilar-Erosion hält an</risk>
        </risks>
        <tags>
            <tag>Healthcare</tag>
            <tag>Pharma</tag>
        </tags>
    </report>

</researchReports>
